FDA Approval Summary: Repotrectinib for locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Barbato MI, Bradford D, Ren Y, Aungst SL, Miller CP, Pan L, Fourie Zirkelbach J, Li Y, Bi Y, Fan J, Grimstein M, Dorff SE, Amatya AK, Mishra-Kalyani PS, Scepura B, Schotland P, Udoka O, Ojofeitimi I, Leighton JK, Rahman NA, Pazdur R, Singh H, Kluetz PG, Drezner N.
Barbato MI, et al. Among authors: fan j.
Clin Cancer Res. 2024 Jun 14. doi: 10.1158/1078-0432.CCR-24-0949. Online ahead of print.
Clin Cancer Res. 2024.
PMID: 38875108